Drug
Bbi503
Bbi503: highest development phase Phase 2, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| BBI503 NCT02432690 | Phase 2 | Cancer |
Latest
No recent events.
Follow Bbi503 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.